McKesson CapEx increased by 2.8% to $111.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 34.3%, from $169.00M to $111.00M. Over 4 years (FY 2022 to FY 2026), CapEx shows an upward trend with a 3.0% CAGR.
An increase signals growth investment or infrastructure modernization; a decrease might suggest cost-cutting or a transition to an asset-light model.
Funds used by a company to acquire, upgrade, and maintain physical assets such as property, plants, buildings, technolog...
Hardware-focused tech firms typically have higher CapEx relative to revenue than pure software companies due to manufacturing and supply chain needs.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $93.00M | $93.00M | $67.00M | $135.00M | $71.00M | $86.00M | $108.00M | $125.00M | $78.00M | $75.00M | $90.00M | $188.00M | $106.00M | $136.00M | $126.00M | $169.00M | $111.00M | $106.00M | $108.00M | $111.00M |
| QoQ Change | — | +0.0% | -28.0% | +101.5% | -47.4% | +21.1% | +25.6% | +15.7% | -37.6% | -3.8% | +20.0% | +108.9% | -43.6% | +28.3% | -7.4% | +34.1% | -34.3% | -4.5% | +1.9% | +2.8% |
| YoY Change | — | — | — | — | -23.7% | -7.5% | +61.2% | -7.4% | +9.9% | -12.8% | -16.7% | +50.4% | +35.9% | +81.3% | +40.0% | -10.1% | +4.7% | -22.1% | -14.3% | -34.3% |
| Segment | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q2 '25 |
|---|---|---|---|---|---|---|---|---|
| U.S. Pharmaceutical | $38.50M | $38.50M | $48.25M | $48.25M | $48.25M | $48.25M | $28.00M | $73.00M |
| Medical-Surgical Solutions | $29.25M | $29.25M | $39.75M | $39.75M | $39.75M | $39.75M | $51.00M | $25.00M |
| International | $19.75M | $19.75M | $18.75M | $18.75M | $18.75M | $18.75M | $25.00M | $13.00M |
| Prescription Technology Solutions | $8.75M | — | $7.75M | $7.75M | $7.75M | — | $4.00M | $1.00M |
| Total | $108.00M | $125.00M | $78.00M | $75.00M | $90.00M | $188.00M | $106.00M | $111.00M |
International, Medical-Surgical Solutions, Prescription Technology Solutions, U.S. Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.